Advertisement
Screener

LIGAND PHARMACEUTICALS INCORPORATED (LGNXZ) Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements

2.8 / 5 stars · 68/120 Roast Me

LIGAND PHARMACEUTICALS INCORPORATED Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements

LIGAND PHARMACEUTICALS INCORPORATED (LGNXZ) reported Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements of 0 shares for the 9-month period ending 2022-09-30, per its 10-Q filed 2022-11-08.

Discontinued › Notes

us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements · last filed 2022-11-08

  • LIGAND PHARMACEUTICALS INCORPORATED incremental common shares attributable to dilutive effect of share-based payment arrangements for the quarter ending 2021-09-30 was 379.00K shares.
  • LIGAND PHARMACEUTICALS INCORPORATED incremental common shares attributable to dilutive effect of share-based payment arrangements for the quarter ending 2021-06-30 was 444.00K shares, a 25.88% decline year-over-year.
  • LIGAND PHARMACEUTICALS INCORPORATED incremental common shares attributable to dilutive effect of share-based payment arrangements for the quarter ending 2021-03-31 was 701.00K shares.
  • LIGAND PHARMACEUTICALS INCORPORATED incremental common shares attributable to dilutive effect of share-based payment arrangements for the quarter ending 2020-09-30 was 0.00 shares.
  • LIGAND PHARMACEUTICALS INCORPORATED incremental common shares attributable to dilutive effect of share-based payment arrangements for fiscal 2020 was 0.00 shares, a 100.00% decline from fiscal 2019.
  • LIGAND PHARMACEUTICALS INCORPORATED incremental common shares attributable to dilutive effect of share-based payment arrangements for fiscal 2019 was 719.00K shares, a 36.09% decline from fiscal 2018.
  • LIGAND PHARMACEUTICALS INCORPORATED incremental common shares attributable to dilutive effect of share-based payment arrangements for fiscal 2018 was 1.13M shares, a 12.50% increase from fiscal 2017.
  • LIGAND PHARMACEUTICALS INCORPORATED incremental common shares attributable to dilutive effect of share-based payment arrangements for fiscal 2017 was 1.00M shares.
Period endIncremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements 3 monthIncremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements 3 month as first filedIncremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements 6 monthIncremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements 6 month as first filedIncremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements 9 monthIncremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements 9 month as first filedIncremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements 12 monthIncremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements 12 month as first filed
2022-09-300.00 shares
10-Q · filed 2022-11-08
2021-09-30379.00K shares
10-Q · filed 2021-11-09
507.00K shares
10-Q · filed 2022-11-08
2021-06-30444.00K shares
10-Q · filed 2021-08-03
572.00K shares
10-Q · filed 2021-08-03
2021-03-31701.00K shares
10-Q · filed 2021-05-06
2020-12-310.00 shares
10-K · filed 2021-02-24
2020-09-300.00 shares
10-Q · filed 2021-11-09
0.00 shares
10-Q · filed 2021-11-09
2020-06-30599.00K shares
10-Q · filed 2021-08-03
0.00 shares
10-Q · filed 2021-08-03
2020-03-310.00 shares
10-Q · filed 2021-05-06
2019-12-31719.00K shares
10-K · filed 2021-02-24
2019-09-300.00 shares
10-Q · filed 2020-11-06
728.00K shares
10-Q · filed 2020-11-06
2019-06-300.00 shares
10-Q · filed 2020-08-07
761.00K shares
10-Q · filed 2020-08-07
2019-03-31785.00K shares
10-Q · filed 2020-05-08
2018-12-311.13M shares
10-K · filed 2021-02-24
2018-09-301.25M shares
10-Q · filed 2019-11-08
1.25M shares
10-Q · filed 2018-11-08
1.17M shares
10-Q · filed 2019-11-08
1.17M shares
10-Q · filed 2018-11-08
2018-06-301.13M shares
10-Q · filed 2019-08-08
1.13M shares
10-Q · filed 2018-08-08
1.13M shares
10-Q · filed 2019-08-08
1.13M shares
10-Q · filed 2018-08-08
2018-03-311.12M shares
10-Q · filed 2019-05-09
1.12M shares
10-Q · filed 2018-05-09
2017-12-311.00M shares
10-K · filed 2020-02-27
2017-09-301.02M shares
10-Q · filed 2018-11-08
980.46K shares
10-Q · filed 2018-11-08
2017-06-30967.53K shares
10-Q · filed 2018-08-08
961.02K shares
10-Q · filed 2018-08-08
2017-03-31954.51K shares
10-Q · filed 2018-05-09
2016-12-310.00 shares
10-K · filed 2019-02-28
2016-09-30792.47K shares
10-Q · filed 2017-11-09
788.11K shares
10-Q · filed 2017-11-09
2016-06-300.00 shares
10-Q · filed 2017-08-09
0.00 shares
10-Q · filed 2017-08-09
785.92K shares
10-Q · filed 2016-08-04
2016-03-31759.58K shares
10-Q · filed 2017-05-09
2015-12-31882.00K shares
10-K · filed 2018-03-01
882.38K shares
10-K · filed 2016-02-26
2015-09-30763.86K shares
10-Q · filed 2016-11-14
922.05K shares
10-Q · filed 2016-11-14
2015-06-301.04M shares
10-Q · filed 2016-11-14
1.00M shares
10-Q · filed 2016-11-14
2015-03-31957.37K shares
10-Q · filed 2016-11-14
2014-12-31978.00K shares
10-K · filed 2017-02-28
80.10K shares
10-K · filed 2014-12-01
2014-09-30905.59K shares
10-Q · filed 2015-11-09
1.01M shares
10-Q · filed 2015-11-09
2014-06-301.01M shares
10-Q · filed 2015-08-05
1.06M shares
10-Q · filed 2015-08-05
2014-03-31546.74K shares
10-Q · filed 2015-05-11
2013-12-31352.96K shares
10-K · filed 2016-11-14
80.10K shares
10-K · filed 2014-02-24
2013-09-30408.57K shares
10-Q · filed 2014-10-31
232.31K shares
10-Q · filed 2014-10-31
2013-06-30122.35K shares
10-Q · filed 2014-08-05
46.39K shares
10-Q · filed 2013-08-01
18.27K shares
10-Q · filed 2014-08-05
35.86K shares
10-Q · filed 2013-08-01
2013-03-3116.33K shares
10-Q · filed 2014-05-07
2012-12-310.00 shares
10-K · filed 2015-02-23
57.69K shares
10-K · filed 2014-12-01
2011-12-3157.69K shares
10-K/A · filed 2014-12-12